Danish Pharmacovigilance Update, 16 August 2012

06 September 2012

In this issue of Danish Pharmacovigilance Update:

  • Maximum single dose of intravenous ondansetron (Zofran® and others) now restricted to 16 mg (front page)
  • Correlation between calcitonin and malignant disease – new restrictions on the use and withdrawal of nasal spray from the market (p 2)
  • Risk of impulse control disorders in patients undergoing treatment with dopamine-increasing drugs (p 2)
  • Serious skin reactions correlated to the use of carbamazepine, oxcarbazepine or allopurinol and association with certain genetic alleles (p 3)
  • Reports of suicide correlated to initiation of antidepressants (p 4)
  • Medication errors and incorrect use of Exelon® transdermal patch for treatment of Alzheimer’s dementia (p 5)
  • Short news (pp 5-6)
  • Medicintjek (Medicine check): Mobile app with information about medicines (p 7)

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.